ImmunoMolecular Therapeutics is a private clinical stage biotech company developing a revolutionary therapeutic approach for the treatment of Type I Diabetes.  The company was founded by world class researchers at the Barbara Davis Center for Diabetes.  The company’s proprietary approach to Type I Diabetes interrupts the body’s autoimmune processes that destroy pancreatic beta cells in diabetic patients.  By interrupting these autoimmune processes, the patient maintains the ability to produce insulin normally.  The approach has applications in other diseases related to the body’s autoimmune processes.

1.25M Americans are living with T1D including about 200,000 youth (less than 20 years old) and over a million adults (20 years old and older)¹,²,³

40,000 people are diagnosed with T1D each year in the U.S.¹,²



Steve Orndorff PhD


Aaron Michels MD

Chief Scientific Officer
Scientific Co-Founder

Peter Gottlieb MD

Chief Medical Officer
Scientific Co-Founder

Greg Kading

View full biographies

Dr. Orndorff is a serial entrepreneur with more than 30 years experience in the biotechnology industry. Previously he was CEO of MicroBiome Therapeutics, a clinical stage company developing gut microbiome modulators for Type 2 diabetes and earlier he was founder and CEO of Ariel Pharmaceuticals, a specialty pharmaceutical company focused on clinical development of GPCR-EP4 receptor antagonists for migraine and chronic pain. He was also founder and CEO of Accera and Univera Pharmaceuticals. He is past Chairman of the Colorado Institute for Drug, Device & Diagnostic Development and is a founder and past Chairman of the Colorado BioScience Association, as well as a past President of the Society for Industrial Microbiology. Dr. Orndorff received a B.S. degree in biology from Virginia Polytechnic Institute and a Ph.D. in microbiology from the University of Maryland.


Aaron Michels MD is an Assistant Professor of Pediatrics & Medicine at the University of Colorado Denver, the Frieda and George S. Eisenbarth Clinical Immunology Endowed Chair, Director of Clinical Immunology at the Barbara Davis Center for Diabetes, and a practicing endocrinologist. Dr. Michels is active in Diabetes research and has authored or co-authored several articles for peer reviewed journals.  His research focuses on understanding the basic immunology of type 1 diabetes to design specific therapies to prevent and stop the autoimmune destruction of insulin producing cells.  One major focus is on the use of small ‘drug-like’ molecules to inhibit T cell responses involved in beta cell damage.  He is also involved in clinical trials using medications to safely alter the immune system to prevent and treat type 1 diabetes. Dr. Michels has lived with type 1 diabetes for more than 20 years and is committed to caring for patients with diabetes along with pursuing research to prevent and ultimately cure type 1 diabetes.   Dr. Michels earned BS and MD degrees from Creighton University.


Peter Gottlieb, MD is Professor of Pediatrics and Medicine with tenure at the University of Colorado Health Science Center, and Director of Translational Research Unit at the Barbara Davis Center for Diabetes, and a practicing endocrinologist. Dr. Gottlieb is active in diabetes research, and currently serves as an Investigator for Type 1 Diabetes at Trialnet, Center Director for T1D Trialnet research at the University of Colorado, member of the Gastroparesis Clinical Research Consortium Data Safety Monitoring Board at NIDDK/Johns Hopkins, member of the Steering Committee of the T Cell Workshop at Immunology of Diabetes Society, and member of Viacyte Data Safety and Monitoring Board. He has previously served the Juvenile Diabetes Research Foundation as member and President of Board of Trustees Mountain States Region.   Dr. Gottlieb currently serves on the Editorial Board of Diabetes Technology and Therapeutics, the European Journal of Clinical Investigation, and as a reviewer for Current Opinion in Diabetes and Endocrinology, the Journal of Clinical Endocrinology and Metabolism, Diabetes, and Diabetes Care, and has authored or co-authored numerous publications in peer reviewed journals.   Dr. Gottlieb earned a BS degree, Cum Laude, from University of Pennsylvania and MD degree from Robert Wood Johnson Medical School.


Greg has worked with a variety of early and mid-stage businesses in the areas of financial planning and analysis, investment analysis, and financing.  He focuses on helping companies understand the financial impact of strategic and tactical decisions and helps companies focus on the few key metrics that matter to improve performance.  Most recently, Greg was head of finance for a venture backed bio-technology company in which he led the company’s development of support processes.  His work enabled the company to execute on the commercial launch of its first product.  In this role he closed financings totaling over $50 million, hired and mentored key staff in accounting, HR, and IT, and implemented an ERP system while the company grew from 4 employees to 65 employees.  Previously, Greg was a two time President’s club winner with a predecessor company to CenturyLink while working in a variety of finance positions.   While there he led the financial planning for the company’s entry into Cable TV services and ultimately became the business unit’s CFO.  He has been an adjunct instructor in finance at Metro State University in Denver and Arapahoe Community College.  Greg was awarded the Chartered Financial Analyst designation from the CFA Institute.   An Iowa native, Greg holds a B.S. in Industrial Engineering from Iowa State University, and an M.B.A. degree from Creighton University.


While insulin injections or infusion allow a person with T1D to stay alive, they do not cure the disease, nor do they necessarily prevent the possibility of the disease’s serious effects, which may include: kidney failure, blindness, nerve damage, heart attack, stroke, and pregnancy complications.